Letters to the Editor

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna
Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston
Center for Molecular Medicine (CeMM), Austrian Academy of Sciences, Vienna
Centre Hospitalier Universitaire de Québec – Université Laval and Faculty of Pharmacy, Université Laval, Québec
Centre Hospitalier Universitaire de Québec – Université Laval and Faculty of Pharmacy, Université Laval, Québec
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna
UMR CANTHER, INSERM 1277-CNRS 9020 UMRS 12. University of Lille, Hematology Laboratory, Biology and pathology center, CHU de Lille, 59000 Lille
Service d'Hematologie Clinique et de Therapie Cellulaire, CHU, Universite Clermont Auvergne, EA7453 CHELTER, CIC1405, Clermont Ferrand
Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna
Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston
Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna
Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna
3rd Medical Department, Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna
1. Medical Department, Center for Oncology and Hematology, Wilhelminenhospital Vienna, Vienna
Department of Laboratory Medicine, Medical University of Vienna
Department of Medicine I, Division of Oncology, Medical University of Vienna
Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna
Clinical Department of Pathology, Medical University of Vienna
Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna
Center for Molecular Medicine (CeMM), Austrian Academy of Sciences, Vienna
Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston
Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna
Haematologica Early view Feb 25, 2021 https://doi.org/10.3324/haematol.2020.271304